Screener
Cytokinetics CYTK Commercial Milestone — Maximum Milestone Additional Amount Receivable
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:MaximumMilestoneAdditionalAmountReceivable.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
The Company earned €10.0 million in the first quarter of 2026 and remains eligible to receive up to an additional €70.0 million upon achievement of development and commercial milestones. The Company is also eligible to receive up to an additional €490.0 million in commercial milestone payments upon the achievement of certain sales milestones, and tiered royalties on net sales of aficamten in Japan.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's commercial milestone — maximum milestone additional amount receivable?
- Cytokinetics (CYTK) reported commercial milestone — maximum milestone additional amount receivable of $490M in Q2 2026.
- What does commercial milestone — maximum milestone additional amount receivable mean?
- This metric represents the total potential future cash inflows contingent upon the successful achievement of specific commercial performance targets or regulatory milestones for a licensed product or therapeutic asset. It quantifies the maximum remaining contractual payments the company is entitled to receive from partners or collaborators upon reaching defined market penetration or sales thresholds. This figure serves as a key indicator of the long-term value realization potential embedded within the company's existing licensing and collaboration agreements.
Ask your AI about Cytokinetics's commercial milestone — maximum milestone additional amount receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude